CGON (CG Oncology) Cash Flow from Others : $-5.01 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Cash Flow from Others?

CG Oncology's cash flow from others for the three months ended in Dec. 2024 was $1.25 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.01 Mil.

CG Oncology Cash Flow from Others Historical Data

The historical data trend for CG Oncology's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Cash Flow from Others Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Cash Flow from Others

0.03

0.51

-2.06

-5.01

CG Oncology Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash Flow from Others	Get a 7-Day Free Trial					-1.46	-2.20	-2.48	-1.59	1.25

CG Oncology Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.01 Mil.

CG Oncology Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of CG Oncology's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.